On this page
The retailers selling calcium alpha-ketoglutarate all tell the same story: pure AKG is unstable, breaks down in your stomach, and calcium binding fixes both problems. It is a tidy story that captures roughly half of what actually matters.
The other half is a comparison the retailer coverage almost universally dodges: not Ca-AKG vs free AKG, but delayed-release Ca-AKG vs standard Ca-AKG. That comparison has real human data behind it — and it changes the answer to "which one should I take" more than the free-vs-bound question does.
This guide walks through both distinctions honestly. For the wider evidence overview, see our pillar: calcium alpha-ketoglutarate — the complete evidence-based guide. Every citation links back to a paper page in our Ca-AKG Data Center.
Ca-AKG and free AKG in one sentence each
Ca-AKG is alpha-ketoglutarate bound to a calcium ion as a stable salt. This is what nearly every longevity supplement on the market sells.
Free AKG is alpha-ketoglutarate on its own — the unbound acid form, sometimes called plain AKG or unbound AKG. Sold mostly as bulk powder to a small niche of experimental users, rarely in capsule form.
Both compounds deliver the same active molecule. The question is whether the calcium binding matters — and the answer is more nuanced than either the retailer marketing or the pure-molecule purists suggest.
What is free AKG?
Alpha-ketoglutarate is a carboxylic acid — a small organic molecule with two acidic groups. In its pure "free acid" form it is chemically reactive and hygroscopic (it absorbs water from the air). Left in bulk powder without a stabilising partner molecule, it degrades over time and is unpleasant to handle. This is why almost every supplement form of AKG on the market is a salt of some kind — bound to calcium, arginine, ornithine, sodium, or occasionally creatine. For a full walkthrough of every commercially sold form, see AKG forms explained.
Free AKG powder is available. Longevity forum users sometimes buy it because it is cheaper per gram of AKG than the calcium-bound version and because it avoids the added calcium load. But the free acid form is inconvenient to dose (bitter, hygroscopic, degrades in humid conditions), and nobody has demonstrated any advantage from using it instead of Ca-AKG.
What does the calcium actually do?
Three things.
It stabilises the molecule for storage. Binding AKG to calcium as a salt makes the compound less reactive, less hygroscopic, and easier to package into a capsule that will still contain intact AKG when you open the bottle 18 months later. This is settled formulation chemistry, not a marketing claim.
It changes what happens in the stomach. A stable calcium salt survives the stomach's acidic environment better than a free carboxylic acid would. Once the salt dissolves in the small intestine, calcium and AKG go their separate ways. How much difference this actually makes to systemic AKG availability in humans has not been directly measured in a head-to-head trial — but the inference from basic salt chemistry is reasonable.
It adds calcium. Around 200 mg of elemental calcium per 1 g of Ca-AKG. Small enough to be ignored if you are not otherwise supplementing calcium. Meaningful enough to factor in if you already take a calcium supplement, eat a fortified diet, or have a history of kidney stones. See what is Ca-AKG for the calcium-vs-molecule breakdown in plain English.
Ca-AKG vs free AKG: what the evidence shows (and doesn't)
The honest answer is: less than the retailer marketing implies.
What we have. Every study underpinning the modern longevity case for AKG used Ca-AKG or a delayed-release Ca-AKG formulation specifically. The 2020 Buck Institute mouse study used food-incorporated Ca-AKG [2]. The Rejuvant retrospective used delayed-release Ca-AKG [3]. The ABLE trial protocol tests delayed-release Ca-AKG. The Chinese trial NCT07114536 tests Ca-AKG. None of these used free unbound AKG in humans.
The foundational mechanistic work in C. elegans, published in Nature in 2014, did use free AKG dissolved in the worms' feeding media [6]. That result establishes the mechanism at a biological level — but worms feeding in liquid have entirely different absorption biology to humans swallowing a capsule.
What we don't have. A single peer-reviewed head-to-head pharmacokinetic trial of Ca-AKG versus free AKG in humans. Nobody has directly measured whether the calcium salt actually raises plasma AKG more, or for longer, or in different tissues than the free acid would. The 2022 review in Trends in Endocrinology and Metabolism catalogues the human AKG literature comprehensively — but does not include a comparative bioavailability trial [5]. The historical clinical review in Archivum Immunologiae et Therapiae Experimentalis similarly documents Ca-AKG's decades of clinical use without ever comparing it head-to-head against a free AKG arm [4].
The retailer claim that "pure AKG breaks down rapidly in the bloodstream while Ca-AKG doesn't" is not supported by a published human pharmacokinetic comparison. It rests on inference from the formulation chemistry — reasonable inference, but inference.
The comparison the retailers dodge: delayed-release Ca-AKG vs standard Ca-AKG
This is the comparison that has real human data, and the one that should actually shape your purchase decision.
In May 2026, a team led by researchers at the National University of Singapore published the largest human dataset on Ca-AKG to date — an Aging Cell analysis of 4,260 exceptionally healthy adults who had done at least one saliva-based DNA methylation age test between 2020 and 2025. The researchers looked at the association between 84 different supplements and biological age [1].
Delayed-release Ca-AKG — the Rejuvant formulation — showed the largest association of any supplement tested. Users had a biological age approximately 1.8 years lower than expected on average, after adjusting for age, sex, smoking status, and self-reported health.
Standard immediate-release Ca-AKG showed an effect approximately 8 times smaller and did not reach statistical significance.
Read that again. In the largest available human dataset, the delayed-release proprietary formulation outperformed the standard non-delayed-release formulation by roughly a factor of 8. NAD+ precursors (NMN and NR) showed effects roughly 9 times smaller than delayed-release Ca-AKG and also did not reach significance.
This is an observational cross-sectional analysis, not a randomised trial. Causal inference is limited. A senior author has a financial interest in the manufacturer of the delayed-release product. The finding needs replication in a proper randomised design — which the ABLE trial and the Chinese trial will address over the next 12 to 18 months.
But this is the best comparative human evidence we have. And it suggests the formulation question that matters most is not free AKG vs Ca-AKG — it is standard Ca-AKG vs delayed-release Ca-AKG. The full biological age story lives in Ca-AKG and biological age.
Is there any reason to take free AKG powder?
Three edge cases where free AKG might be defensible:
Cost per gram of AKG. Free AKG powder is cheaper per gram of actual AKG than any salt-bound form. For someone dosing 2 g/day long-term without a delayed-release proprietary product available, the cost difference is real.
Avoiding the calcium load. If you already take a calcium supplement, or have a history of kidney stones, or are on medication that interacts with calcium (some thyroid medications, tetracycline-class antibiotics, certain bisphosphonates), the added calcium in Ca-AKG becomes a genuine consideration. Free AKG or sodium AKG avoids this.
Precision dosing for research purposes. A minority of longevity self-experimenters run precise dose-response experiments on themselves and prefer the pure compound for that reason. This is a small use case.
Outside of these edge cases, free AKG powder does not offer a clear advantage over Ca-AKG. It has no human longevity data behind it. The stability disadvantage is real (bitter taste, absorption of humidity, gradual degradation). And the whole longevity evidence base was built on the calcium-bound form, not the free acid.
Which one should you take?
Three practical positions, in order of defensibility.
Best-evidenced choice: delayed-release Ca-AKG. The Pabis 2026 cohort data, the 2021 Rejuvant retrospective, and the ongoing ABLE trial all use this specific formulation. If you can afford it and can get it, this is the option with the largest human effect signal.
Defensible middle path: standard Ca-AKG. Cheaper, more widely available, and still supported by the mouse lifespan work and the general biology. The 2026 cohort data suggests the biological age effect is much smaller than the delayed-release form — but "much smaller" is not "zero", and the safety profile and dosing precision are equivalent. Suitable if the delayed-release product is unavailable or unaffordable.
Edge case: free AKG powder. Only defensible if you have a specific reason to avoid the calcium load or need bulk cost efficiency. No positive advantage over Ca-AKG on any measured outcome.
For the full buyer's-guide walkthrough of what's actually on the UK and US market, see the best Ca-AKG supplement guide. For the dose-picking question, see Ca-AKG dosage: what the trial data supports. For the AAKG (arginine alpha-ketoglutarate) confusion — different compound entirely — see Ca-AKG vs AAKG. And for the mechanism spine of what any of these forms actually do in the body, see how Ca-AKG works.
Cost comparison
Approximate cost per 1 g dose of AKG delivered, as of late 2026:
| Form | Approx cost per 1 g AKG | Notes |
|---|---|---|
| Delayed-release Ca-AKG (Rejuvant) | £1.50–£2.50 | Proprietary formulation. Premium price. |
| Standard Ca-AKG capsules | £0.20–£0.60 | Widely available. Most common form. |
| Free AKG bulk powder | £0.05–£0.20 | Cheapest per gram. Bitter, hygroscopic. |
The premium for delayed-release Ca-AKG is real — 5 to 10 times the cost of standard Ca-AKG capsules. Whether that premium is justified depends entirely on whether the delayed-release effect is real and sustained across randomised trials. The 2026 Pabis data supports the premium. The ABLE trial and the Chinese trial will either confirm or challenge that support when they read out.
What we still don't know
Three gaps that any honest treatment of this comparison has to acknowledge.
No head-to-head pharmacokinetic study of Ca-AKG vs free AKG in humans has ever been published. The stability and absorption claims for the calcium-bound form rest on inference from salt chemistry, not on comparative human PK data.
The Pabis 2026 comparison of delayed-release vs standard Ca-AKG is cross-sectional and observational. It cannot establish that the delayed-release formulation causes the larger biological age reduction — only that it is associated with it. Randomised head-to-head data does not exist for that comparison either.
Long-term biological age effects when someone stops supplementing have not been studied for any AKG formulation. Whether the delayed-release advantage persists after discontinuation is unknown.
Bottom line
Ca-AKG and free AKG deliver the same active molecule. The calcium binding is a real formulation improvement — better storage stability, better gastric survival, easier dosing — but the head-to-head pharmacokinetic data proving a bioavailability advantage in humans does not exist. Inference from salt chemistry supports the claim; direct human PK trials do not confirm it.
The more consequential comparison is delayed-release Ca-AKG vs standard Ca-AKG. In the largest available human dataset, delayed-release outperformed standard by roughly a factor of 8 on biological age reduction. That is the finding that should drive purchase decisions until the randomised trials read out and either confirm or overturn it.
For most people, standard Ca-AKG remains a reasonable and defensible choice. Delayed-release Ca-AKG carries the strongest human signal and the price premium to match. Free AKG powder is a niche option for specific edge cases. All three deliver the same underlying molecule — but not, on current evidence, to the same effect. The rest of the picture is in the Ca-AKG pillar.